主任医师、讲席教授；内科学、公共卫生管理与护理学博士生导师；深圳市第三人民医院党委副书记、院长；国家感染性疾病临床研究中心主任；美国微生物科学院院士、深圳市首届疫情防控公共卫生专家组组长；教育部长江学者、国家百千万人才工程、“有突出贡献中青年专家”、享受国务院特殊津贴。《智能实验医学(英文)》(《iLABMED》)主编；曾担任复旦大学附属华山医院院长助理、上海市公共卫生临床中心党委书记。入选美国斯坦福大学2021、 2022年、2023年（国内学者微生物学领域第3名）全球前2％顶尖科学家榜单及《终身科学影响力排行榜》。

学术任职：

世界卫生组织新发传染病临床诊治培训与研究合作中心主任；国际流感和呼吸道病毒感染学会(ISIRV)抗病毒小组(AVG)委员

国家疾病预防控制专家委员会委员，国家卫建委艾滋病、流感、埃博拉病毒病、感染病质量控制中心专家，国家新冠病毒病救治专家组与境外抗疫专家组后方支持团队成员

中国性病艾滋病防治协会艾滋病合并结核专业委员会主任委员兼结核病学组组长，中华医学会感染病学分会艾滋病专业学组副组长，中华医学会热带病与寄生虫分会前任主任委员兼艾滋病学组组长，欧美同学会（中国留学人员联谊会）医师协会传染病分会主任委员，上海市医学会感染病学分会前任主任委员

科研成果：

先后承担国家科技重大专项(4项)，国家重点研发计划（2项）、“863”、国家自然科学基金 (7项，包括1项重大项目 )，美国盖茨基金、国家临床重点专科等59项科研课题

以第一作者或通讯作者在国内外发表各类论文500余篇，其中在SCI引用杂志包括Nature、New England Journal of Medicine、Lancet Microbe、Science Translational Medicine发表论著360篇，已主编专业参考书15部

以下为近年成果目录节选：

1.Yang Yang#, Liping Guo#, Jing Yuan#, Zhixiang Xu, Yuchen Gu, Jiaqi Zhang, Yuan Guan, Jinhu Liang, Hongzhou Lu*, Yingxia Liu*. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.529): a prospective cohort study from Shenzhen, China. The Lancet Microbe, 2023, just accepted. IF = 38.2

2.Liping Guo#, Xue Liu#, Yuchen Gu, Jinyan Jiang, Ziyue Yang, Qiuying Lv, Deyin Guo, Yang Yang*, Hongzhou Lu*, Jing Yuan*. Distinct and relatively mild clinical characteristics of SARS-CoV-2 BA.5 infections against BA.2. Signal Transduction & Targeted Therapy, 2023, 8, 171. IF = 39.3

3.Yang Yang*, Xiaohua Gong, Yimin Tang, Jiexiang Liu, Lijiao Zeng, Jiahua Kuang, Fuxiang Wang*, Hongzhou Lu*, Yingxia Liu*. Naive and breakthrough infections with BA.2, BA.5 and BF.7 variants provide poor cross protection against XBB related variants. Journal of Infection, 2023, 87, 156-159. IF = 28.2

4.Fuxiang Wang#, Wen Xiao#, Yimin Tang#, Mengli Cao, Dan Shu, Tetsuya Asakawa, Yechun Xu, Xiangrui Jiang, Leike Zhang, Wei Wang, Jianxing Tang, Yuansheng Huang, Yang Yang, Yumei Yang, Renhong Tang, Jingshan Shen, Hongzhou Lu*. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial. The Lancet Regional Health -Western Pacific, 2023, 38, 100835. IF = 7.1

5.Zixun Lin, Liqin Sun, Cheng Wang, Fuxiang Wang, Jun Wang*, Qian Li*,
Hongzhou Lu*. Bottlenecks and recent advancements in detecting Mycobacterium tuberculosis in patients with HIV. iLABMED, 2023, 1, 44-57.

6.Yang Yang*, Xiaohua Gong, Jun Wang, Shisong Fang, Jiaqi Zhang, Xuejiao Liao, Yuan Guan, Weihua Wu, Yingxia Liu*, Hongzhou Lu*. Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2022, 7, 316. IF = 38.104

7.Xiaohe Li, Liwen Wu, Youzhi Qu, Mengli Cao, Jiaqi Feng, Hua Huang, Yi Liu, Hongzhou Lu*, Quanying Liu*, Yingxia Liu*. Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children. Signal Transduction and Targeted Therapy, 2022, 7, 203. IF = 38.104

8.Shuai Yang, Yun Ling, Fang Zhao, Wei Li, Zhigang Song, Lu Wang, Qiuting Li, Mengxing Liu, Ying Tong, Lu Chen, Daoping Ru, Tongsheng Zhang, Kaicheng Zhou, Baolong Zhang, Peng Xu, Zhicong Yang, Wenxuan Li, Yuanlin Song, Jianqing Xu, Tongyu Zhu, Fei Shan*, Wenqiang Yu*, Hongzhou Lu*. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduction and Targeted Therapy, 2022, 7, 91. IF = 38.104

9.Xiaoyu Sun, Chunyan Yi, Yuanfei Zhu, Longfei Ding, Shuai Xia, Xingchen Chen, Mu Liu, Chenjian Gu, Xiao Lu, Yadong Fu, Shuangfeng Chen, Tianlong Zhang, Yaguang Zhang, Zhuo Yang, Liyan Ma, Wangpeng Gu, Gaowei Hu, Shujuan Du, Renhong Yan, Weihui Fu, Songhua Yuan, Chenli Qiu, Chen Zhao, Xiaoyan Zhang, Yonghui He, Aidong Qu, Xu Zhou, Xiuling Li, Gary Wong, Qiang Deng, Qiang Zhou, Hongzhou Lu, Zhiyang Ling*, Jianping Ding*, Lu Lu*, Jianqing Xu*, Youhua Xie*, Bing Sun*. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nature Microbiology, 2022, 7, 1063-1074. IF = 30.694

10.YangYang, Xiaohua Gong, Liuqing Yang, Jie Li , Jiaqi Zhang ,Lanlan Wei, Guoguo Ye , Yimin Tang , Yujing Jiang , Jianhuan Li , Yuanlong Lin , Fuxiang Wang, Hongzhou Lu*, Yingxia Liu. Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees. Journal of Infection, 2022, 84, 579-613 IF = 38.637

11.Yingdan Wang, Meiqin Liu, Yaping Shen, Yunping Ma, Xiang Li, Yuanyuan Zhang, Mei Liu, Xing-Lou Yang, Jun Chen, Renhong Yan, Die Luan, Yanqun Wang, Ying Chen, Qimin Wang, Haofeng Lin, Yaning Li, Kaiyue Wu, Tongyu Zhu, Jincun Zhao, Hongzhou Lu*, Yumei Wen*, Shibo Jiang*, Fan Wu*, Qiang Zhou*, Zheng-Li Shi*, Jinghe Huang*. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses. Cell Discovery, 2022, 8, 36. IF = 38.079 

12.Shanhe Yu, Caixia Di, Shijun Chen, Mingquan Guo, Jiayang Yan, Zhaoqin Zhu, Li Liu, Ruixue Feng, Yinyin Xie, Ruihong Zhang, Juan Chen, Mengxi Wang, Dong Wei, Hai Fang, Tong Yin, Jinyan Huang, Saijuan Chen, Hongzhou Lu*, Jiang Zhu*, Jieming Qu*. Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2(pos) subjects. Cell Research, 2021, 31, 1148-1162. IF = 46.297

13.Lu Li, Jingyan Tang, Zhiwei Xie, Qingxin Gan, Guofang Tang, Zhongwei Hu, Huimin Zeng, Jingrong Shi, Jiaojiao Li, Yan Li, Changwen Ke, Min Kang, Dan Liang, Huan Lu, Yuwei Tong, Xilong Deng, Jinxin Liu, Hongzhou Lu, Fuxiang Wang, Fengyu Hu, Feng Li, Nanshan Zhong, Xiaoping Tang. Characteristics of SARS-CoV-2 Delta variant-infected individuals with intermittently positive retest viral RNA after discharge. National Science Review, 2022,9, nwac141. IF = 20.6

14.Chunyan Yi, Zhiyang Ling, Xiao Lu, Yadong Fu, Zhuo Yang, Sonam Wangmo, Shuangfeng Chen, Yaguang Zhang, Liyan Ma, Wangpeng Gu, Hongzhou Lu*, Xiaoyu Sun*, Bing Sun*. A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues. Cellular & Molecular Immunology, 2022, 19, 647-649. IF = 21.235

15.Liu Cao, Yingjun Li, Sidi Yang, Guanguan Li, Qifan Zhou, Jing Sun, Tiefeng Xu, Yang Yang, Ruyan Liao, Yongxia Shi, Yujian Yang, Tiaozhen Zhu, Siyao Huang, Yanxi Ji, Feng Cong, Yinzhu Luo, Yujun Zhu, Hemi Luan, Huan Zhang, Jingdiao Chen, Xue Liu, Renru Luo, Lihong Liu, Ping Wang, Yang Yu, Fan Xing, Bixia Ke, Huanying Zheng, Xiaoling Deng, Wenyong Zhang, Chuwen Lin, Mang Shi, Chun-Mei Li, Yu Zhang, Lu Zhang, Jun Dai, Hongzhou Lu, Jincun Zhao, Xumu Zhang, Deyin Guo. The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants. Science Translational Medicine, 2022, 14, eabm7621. IF = 17.956 

获奖情况：

入选美国斯坦福大学2021全球前2％顶尖科学家榜单（World’s Top2％ Scientists 2021）及《终身科学影响力排行榜》，获2020法国国家科学院“夏邦克-杜博赛”奖国家科学技术特等奖，上海科技成果一等奖，上海医学科技一等奖等，国家级、省部级科技成果奖10余项；获专利19项。2022年获“人民名医•卓越建树”奖；教育部长江学者，国家百千万人才工程，“有突出贡献中青年专家”，深圳市国家级领军人才，全国道德模范与身边好人（中国好医生），“白求恩式好医生”，科学中国人2016年度人物，“最美援外医生”，“影响中国”2014年度科技人物，2014年度“一健康基金”特别奖，2020年度“一健康基金”优秀教师一等奖。先后荣获全国医药卫生系统先进个人，全国抗击“非典”先进个人，“公卫先锋”奖，“上海市优秀共产党员”，上海市“人道博爱奖”，中国医药科技创新人物，团中央与全国学联“中国大学生跨世纪发展奖励基金”，“上海领军人才”，“上海市优秀学科带头人”，“上海市医学领军人才”，上海市“五一劳动奖章”获得者，上海市卫生系统“银蛇奖”，“仁心医者-上海市杰出专科医师奖”，“医务工匠”，文明职工，“创新之星”，“优秀发明银奖”，上海市卫生局先进工作者并行政记大功一次，上海市科委“明治乳业科学奖”，美国肝病学会-亚太肝病学会奖，艾滋病国际倡导联盟“精忠奖”。

代表性研究（2023年）：

1.HIV/TB诊断进展与甲流肝损伤风险研究

2.近红外AIEgen探针快速、即时诊断结核病

授权专利（2023年）：

1、国家发明专利：磁分离微流控芯片装置及其制备方法与应用

本发明涉及生物医用工程技术领域，公开一种磁分离微流控芯片装置及其制备方法与应用，其中，装置包括芯片夹具和微流控芯片；本发明通过设置软磁体把强磁铁更密的磁场线引到更靠近微流道附近，从而影响微流道内部的纳米磁珠移动轨迹，能有效实现强磁性细胞、弱磁性细胞及无磁性细胞的分离富集。